Skip to main content
MyDeficiencies

Lacosamide

Sodium-channel anticonvulsant (functionalized amino acid)

Also sold as Vimpat.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Lacosamide has no documented classical depletion machinery, and that absence is itself load-bearing for how this dossier reads the circulating claims about it. Its FDA label (via DailyMed, read directly this session) shows hepatic metabolism through CYP3A4, CYP2C9, and CYP2C19 to an inactive metabolite, roughly 40 percent of a dose excreted unchanged in urine, about 100 percent oral bioavailability, and no documented induction or inhibition of any CYP450 enzyme by lacosamide itself. This matters specifically because this project's sibling anticonvulsant dossiers (phenytoin, primidone, phenobarbital-class agents, and zonisamide) document a real, Tier A/B, enzyme-induction-mediated vitamin D, folate, and vitamin K depletion pattern for the older, enzyme-inducing agents. Lacosamide is a newer agent with a different mechanism (slow-inactivation enhancement of voltage-gated sodium channels, plus a secondary CRMP2-binding action) and, per the cohort test this protocol requires before any class extrapolation, its own hepatic metabolism and CYP profile were checked directly against the label rather than assumed: no induction is documented. That specific mechanism is not present here, and this dossier does not extend the older-generation pattern to lacosamide by default.

Sodium-channel anticonvulsant (functionalized amino acid) · ATC N03AX18 · also sold as Vimpat · reviewed 2026-10-02. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Lacosamide in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Red tier

Red — Severe

See study details

No nutrient or category in this dossier reached red.

Full detail and limits

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. Empty

Limits on what this shows

  • What would fill this tier: Two or more independent human studies, each with lacosamide-treated patients specifically in the cohort, directly measuring a nutrient or validated functional marker, with consistent direction and a named mechanism.

Why empty

Red requires at least two independent Tier A drug-specific sources with the nutrient directly measured in a human cohort, consistent direction, and a named mechanism. Lacosamide's own pharmacokinetic profile documents no CYP450 induction, no absorption-interference mechanism, and no renal-tubular-wasting mechanism, so there is no classical depletion pathway to expect a Tier A human signal from in the first place, and no Tier A human study measuring any of the seven mandatory categories in lacosamide-treated patients was located this session.

Orange tier

Red — Severe

See study details

No nutrient or category in this dossier reached orange.

Full detail and limits

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. Empty

Limits on what this shows

  • What would fill this tier: A Tier A, lacosamide-specific human study directly measuring a nutrient or the seven mandatory categories and finding a real but bounded deficit, for example limited to a defined exposure window, dose, or subgroup.

Why empty

Orange requires at least one Tier A drug-specific source showing a real, bounded deficit. The one Tier A, drug-specific, physiologically adjacent finding located this session, the label's PR-interval/AV-conduction signal, is the drug's own intended-class cardiac pharmacology (Hard Rule 2), not a nutrient-mediated deficit, and is routed to the Monitoring panel instead of graded here.

Sodium / fluid balance, case-report-level hyponatremia signal (clinical details not independently confirmed this session)

Yellow — Low

See study details

A case report titled "Lacosamide: Associated Hyponatremia" exists in the peer-reviewed literature, confirmed by title, authors, journal, and DOI via a completed Crossref search; the article's own text could not be opened this session, so no dose, sodium level, timeline, or rechallenge detail is claimed here, but the title itself names lacosamide directly and satisfies this protocol's cohort test without requiring the full text.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: The label itself, read in full, reports no hyponatremia or SIADH signal across lacosamide's clinical trial program, which is a genuine, disclosed counterpoint to the single case report: a Tier A negative from a larger population against a Tier B positive from one case.
  • At-risk subgroups: Not identifiable; the case report's own details were not accessible this session.
  • Counter-evidence on record: See Key negative/null findings: the label's silence on hyponatremia across the broader trial population. No second lacosamide-specific hyponatremia case report or series was located (a follow-up Crossref search for additional lacosamide/SIADH reports was rate-limited before completing, so this is a single-source finding, not a confirmed case series).

Regulatory status

Not addressed in the FDA label: the label itself was re-read in full this session via WebFetch and contains no mention of sodium, hyponatremia, SIADH, or related electrolyte disturbance (a genuine Tier A negative from the label, disclosed alongside the positive case-report signal below rather than letting one silently override the other).

Population evidence

Tier B by definition (case report, this medication specifically): Gupta SS, Patti R, Lindsay D, Raheja H, Kupfer Y. "Lacosamide: Associated Hyponatremia." American Journal of Therapeutics. 2018. DOI 10.1097/mjt.0000000000000745. Found and confirmed via a completed Crossref API bibliographic search (title, author list, journal, year, and DOI read directly from the Crossref record this session). The title names lacosamide as the sole subject, not a drug class, which is what satisfies the cohort test here; a doi.org resolver attempt to open the article itself returned an HTTP 402 payment-required paywall response, and three follow-up attempts (a Crossref works/{doi} metadata lookup, a PubMed search, and a Semantic Scholar search) were each rejected with HTTP 429 rate-limiting before completing. No patient count, dose, sodium nadir, timeline, or rechallenge outcome from the case itself is known or claimed.

Mechanism

Named at the class level, not confirmed for this specific case: Step 2 mechanism F (dilutional or hormonal disturbance, SIADH-type) is a documented concern for some other sodium-channel-active anticonvulsants (carbamazepine, oxcarbazepine), making a lacosamide case report of hyponatremia mechanistically plausible; the case report itself was not opened, so whether its authors measured or asserted a SIADH-type mechanism specifically is not confirmed.

Counter-evidence held on record

This is a dilutional/retention-type electrolyte signal, not a dietary sodium deficiency, and must never be read as a reason to increase sodium or fluid intake; per Hard Rule 5, if this mechanism is real, supplementation would be the hazard, not the remedy. It rests on one case report whose own text could not be verified this session, graded no higher than yellow in any case because a case report is Tier B by definition regardless of what its full text would show.

  • Gupta SS, Patti R, Lindsay D, Raheja H, Kupfer Y. Lacosamide: Associated Hyponatremia. American Journal of Therapeutics. 2018. — Case report; title, authors, journal, and year confirmed directly via a completed Crossref API bibliographic search this repair pass. Used as the sole support for the Sodium/fluid balance entry (yellow); the title itself, naming lacosamide directly rather than a drug class, is what satisfies this protocol's cohort test, since the full case report could not be opened. Access note: a doi.org resolver request for this DOI returned an HTTP 402 payment-required paywall response. Three follow-up attempts to retrieve the abstract or full text, a Crossref works/{doi} metadata lookup, a PubMed search, and a Semantic Scholar search, were each rejected with HTTP 429 rate-limiting before completing. No dose, sodium level, timeline, or rechallenge detail from the case itself is known or cited anywhere in this dossier.Access note: a doi.org resolver request for this DOI returned an HTTP 402 payment-required paywall response. Three follow-up attempts to retrieve the abstract or full text, a Crossref works/{doi} metadata lookup, a PubMed search, and a Semantic Scholar search, were each rejected with HTTP 429 rate-limiting before completing. No dose, sodium level, timeline, or rechallenge detail from the case itself is known or cited anywhere in this dossier.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, protective/reverse-direction finding in an Alzheimer's disease neuron model

Yellow — Low

See study details

Lacosamide, used as a CRMP2-binding tool compound, reduced mitochondrial fragmentation and improved organelle motility in cultured Alzheimer's disease model neurons and postmortem AD brain tissue: a protective, reverse-direction finding, not a depletion signal, and not yet shown in lacosamide-treated epilepsy patients.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None identified this session. A dedicated counter-evidence search for null or contradicting lacosamide-mitochondria findings specifically (beyond the general searches recorded under Channels tried for the ungraded entries below) was not separately completed before this session's rate-limiting became severe; this is disclosed rather than presented as a clean negative search.
  • At-risk subgroups: Not applicable; this is a disease-model mechanistic study, not a human lacosamide-treated population, so no patient subgroup can be identified from it.
  • Counter-evidence on record: None found. See Key negative/null findings above for the limitation on how thoroughly counter-evidence was pursued for this specific entry.

Regulatory status

Not addressed in the FDA label; this is an independent mechanistic literature finding, not a labeled effect.

Population evidence

Tier B: in vitro study using cultured cortical neurons from APP/PS1 transgenic (Alzheimer's disease model) mice, supplemented by analysis of postmortem human AD brain tissue. Lacosamide was used directly as the pharmacological agent tested (a CRMP2 ligand), not merely referenced. Brustovetsky T, Khanna R, Brustovetsky N. "CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer's Disease." 2023. PMID 37174687.

Mechanism

Lacosamide binds CRMP2 (collapsin response mediator protein 2) and reduces its phosphorylation, which decreased Drp1 recruitment to mitochondria, diminished mitochondrial fragmentation, improved organelle motility, and protected cultured cortical AD neurons from cell death.

Counter-evidence held on record

This is a mechanistic, disease-model finding in which lacosamide is used as a laboratory tool to block CRMP2, not a clinical finding in lacosamide-treated epilepsy patients, and it must not be read as evidence that taking lacosamide protects against mitochondrial aging or neurodegenerative disease in ordinary use, nor as a rationale for off-label use. It is included because the protocol requires evaluating this category from the literature directly rather than skipping it when no classical mechanism is obvious, and a real, drug-specific, reverse-direction result is exactly the kind of finding this category screen exists to catch.

  • Brustovetsky T, Khanna R, Brustovetsky N. CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer's Disease. 2023. — In vitro study, cultured cortical neurons from APP/PS1 transgenic mice, plus postmortem human AD brain tissue analysis; full abstract read directly this session. Used as supporting evidence for the Mitochondrial burden entry (yellow). Access note: journal name, volume, and DOI could not be independently re-confirmed on a later follow-up request this session (429 rate-limit rejection); the abstract content itself was successfully retrieved and is used only for what it directly states.Access note: journal name, volume, and DOI could not be independently re-confirmed on a later follow-up request this session (429 rate-limit rejection); the abstract content itself was successfully retrieved and is used only for what it directly states.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, protective/reverse-direction finding bounded mostly to combination therapy

Yellow — Low

See study details

Lacosamide, most clearly in combination with pregabalin or piracetam, reduced hippocampal oxidative-stress markers and improved antioxidant enzyme levels in a rat lithium-pilocarpine status-epilepticus model: a protective, reverse-direction finding, bounded by the combination-therapy design.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: The triple combination adding scopolamine (L/P/S) made behavioral deficits worse rather than better, an explicit negative finding for that specific combination, recorded here as a counter-example within the same study rather than omitted.
  • At-risk subgroups: Not applicable; animal model, not a human patient population.
  • Counter-evidence on record: None found beyond the L/P/S negative finding above. A dedicated search for human or lacosamide-monotherapy-only null results on oxidative stress was not separately completed before rate-limiting became severe; disclosed rather than presented as a clean negative search.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier B: rat lithium-pilocarpine status-epilepticus model, lacosamide alone (L, 80 mg/kg) and in combination with pregabalin (L/P, 50/50 mg/kg), piracetam (L/Pi, 50/140 mg/kg), or scopolamine (L/P/S, 50/50/2 mg/kg), dosed over a 6-week time course post-status-epilepticus. Shakeel W, et al. "Time course evaluation of lacosamide alone and in polypharmacy on behavioral manifestations and oxidative stress." J Physiol Pharmacol. 2020;71(4). PMID 33316769. Abstract read in full this session.

Mechanism

L/P and L/Pi treatment significantly reduced hippocampal 8-isoprostanes (measured by real-time microdialysis) and malondialdehyde (MDA); superoxide dismutase (SOD) and glutathione peroxidase (GPx) were significantly improved specifically in the L/P group. The abstract does not separately report statistical significance for oxidative markers in the lacosamide-monotherapy (L) arm alone, distinct from the combination arms; this bound is stated explicitly rather than inferred.

Counter-evidence held on record

This is an animal model of status epilepticus, not routine human maintenance therapy for partial-onset seizures, and the clearest antioxidant benefit was seen in combination-therapy groups, not clearly isolated to lacosamide monotherapy. It must not be read as a human antioxidant-supplementation rationale, and no supplement dose is implied or recommended by this finding.

  • Shakeel W, Rahman SU, Rauf K, et al. Time course evaluation of lacosamide alone and in polypharmacy on behavioral manifestations and oxidative stress in a lithium-pilocarpine model of status epilepticus. J Physiol Pharmacol. 2020;71(4). — Rat lithium-pilocarpine status-epilepticus model; lacosamide alone (80 mg/kg) and in combination with pregabalin, piracetam, or scopolamine; full abstract read directly this session. Used as supporting evidence for the Oxidative stress entry (yellow).

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No grade assigned: no mechanism identified at Step 2, no confirmed Tier B/C evidence, and no circulating consumer claim located to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: No present mechanism connecting lacosamide's sodium-channel/CRMP2 pharmacology to copper handling was identified from the label or any source opened this session (no chelation, no ceruloplasmin or copper-dependent enzyme interaction described anywhere). Two independently completed searches (an original-pass PubMed combined query and a repair-pass Crossref combined query) both returned no lacosamide-specific result. No circulating consumer claim linking lacosamide to copper status was located. The dual condition for ungraded (Step 7) is now met on two genuinely completed clean searches across two different hosts, a stronger basis than the original pass alone.

Channels tried

Original pass, PubMed search-listing page, combined query "lacosamide copper OR lacosamide iron OR lacosamide hemoglobin": completed successfully, returned two results, neither isolating lacosamide and copper (see Iron entry for the same two results). Repair pass, Crossref API, combined query "lacosamide copper iron": completed successfully via WebFetch and returned ten results, all irrelevant (pharmacopeia/formulary monograph entries for lacosamide itself, such as USP and BNF listings, plus unrelated metallurgy standards for copper/iron content testing); no lacosamide-specific copper study of any kind. DailyMed/FDA label: re-read in full this session via WebFetch; confirmed no mention of copper or ceruloplasmin. Europe PMC REST API, Semantic Scholar graph API, OpenAlex bulk search, NCBI eutils: all returned 429/403 proxy-level rejections on repair-pass attempts (confirmed in this session's own agent-proxy status log as organization-policy connection denials); PubMed's search-listing page itself also returned a 429 on this repair pass's one attempt and was not retried per the proxy's explicit instruction not to. NCBI Bookshelf (StatPearls): the one direct attempt this session resolved to an unrelated Bouveret-syndrome article, not a lacosamide page. General WebSearch: unavailable this session (budget fully exhausted, 200 of 200, confirmed independently by a direct tool call this repair pass).

Assessment

A genuine gap with moderate confidence: two independently completed, clean searches on two different hosts (PubMed and Crossref) both found no lacosamide-copper signal, though neither searched a true copper-only single term and several API channels remain tooling-blocked rather than cleanly exhausted. Re-check with a dedicated single-term query once PubMed, Europe PMC, Semantic Scholar, or OpenAlex access recovers.

Iron

Not graded — disclosed evidence gap

See study details

No grade assigned: no mechanism identified at Step 2, no confirmed Tier B/C evidence, and no circulating consumer claim located to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: No present mechanism connecting lacosamide's pharmacology to iron absorption, transport, or storage was identified. The same two independently completed searches described under Copper (an original-pass PubMed query and a repair-pass Crossref query) both covered iron and returned no lacosamide-iron-specific result. The repair pass's new Tier A label finding of postmarketing anemia and neutropenia (graded yellow under Oxygen delivery/utilization) is explicitly not used as support here: anemia is a clinical outcome, not a measured iron deficit, per Hard Rule 2, and no iron-specific marker (ferritin, transferrin saturation, serum iron) was named anywhere located this session. No circulating consumer claim linking lacosamide to iron status specifically was located. The dual condition for ungraded (Step 7) is now met on two genuinely completed clean searches.

Channels tried

Original pass, same combined PubMed query as Copper above ("lacosamide copper OR lacosamide iron OR lacosamide hemoglobin"): completed successfully, two results reviewed, neither lacosamide-iron-specific (see Copper entry for detail). Repair pass, same Crossref combined query as Copper above ("lacosamide copper iron"): completed successfully via WebFetch, ten results, all irrelevant to iron specifically (same pharmacopeia/metallurgy-standard noise described under Copper). DailyMed/FDA label: re-read in full this session; confirmed no mention of iron, ferritin, or transferrin, though it does newly disclose anemia as a postmarketing adverse reaction (see Oxygen delivery/utilization entry; not used to support an iron grade here). Europe PMC, Semantic Scholar, OpenAlex, NCBI eutils, and a repair-pass PubMed attempt: all blocked this session by confirmed organization-level policy denial or 429 rejection (see Copper entry). General WebSearch: unavailable (budget exhausted, confirmed independently this repair pass).

Assessment

A genuine gap with moderate confidence, for the same reasons given under Copper: two independently completed, clean searches on two different hosts found no lacosamide-iron signal, though no true iron-only single-term search was run and several API channels remain tooling-blocked. The new anemia/neutropenia label fact is a real signal but is graded under Oxygen delivery/utilization directly, not carried into this entry, to avoid misfiling a clinical outcome as a nutrient deficiency.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No grade assigned: two completed PubMed searches returned no lacosamide-specific microbiome-composition evidence, and no circulating consumer claim was located to rebut.

Full detail, limits and 2 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: No present mechanism connecting lacosamide's pharmacology to gut microbiome composition or diversity was identified from the label. Three independently completed searches now exist: two original-pass PubMed phrasings and one repair-pass Crossref query, all returning either no result or only unrelated studies, never a lacosamide-specific microbiome finding. No circulating consumer claim linking lacosamide to gut microbiome disruption was located. The dual condition for ungraded (Step 7) is met on a genuinely strengthened, multi-host thoroughness pass.

Channels tried

Original pass, PubMed search-listing page, "lacosamide gut microbiome OR lacosamide microbiota OR lacosamide gut": completed successfully, two results reviewed (PMID 35887145, unrelated bariatric-surgery microbiome study; PMID 42152737, GI motility/ileus case report, not microbiome composition). A second original-pass phrasing, "lacosamide microbiome" alone, hit a reCAPTCHA wall. Repair pass, Crossref API, "lacosamide gut microbiome microbiota dysbiosis": completed successfully via WebFetch, four results, all unrelated to lacosamide (a SARS-CoV-2 dysbiosis review, a diet-and-dysbiosis review, a host-transcriptome microbiome study, and an oral-microbiome book chapter), none mentioning lacosamide at all. This Crossref search independently satisfies the ">1 phrasing" thoroughness bar that the original pass's second PubMed attempt fell short of. Europe PMC, Semantic Scholar, OpenAlex, NCBI eutils, repair-pass PubMed: blocked by confirmed organization-level policy denial or 429 rejection. DailyMed/FDA label: re-read in full; no microbiome-related language. General WebSearch: unavailable (budget exhausted).

Assessment

A genuine literature gap with reasonable confidence: three searches across two independent hosts (PubMed and Crossref), using different phrasings, converge on no lacosamide-specific microbiome finding. The thoroughness requirement is now more solidly met than in the original pass.

  • Pharmacological Incongruity of Lacosamide in the Management of Delirium Complicated by Ileus. Neuropsychopharmacol Rep. 2026. — Title and PMID found via a completed PubMed search-listing page while searching for gut microbiome evidence; concerns GI motility/ileus management, not microbiome composition
  • Impact of Metabolic Surgery on Gut Microbiota and Sera Metabolomic Patterns among Patients with Diabetes. Int J Mol Sci. 2022. — Unrelated bariatric-surgery/diabetes microbiome study surfaced by the same gut-microbiome search; not a lacosamide study

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Oxygen delivery/utilization, postmarketing anemia and neutropenia signal of unestablished frequency and causality

Yellow — Low

See study details

Lacosamide's own FDA label lists neutropenia and anemia under postmarketing adverse reactions: a real, drug-specific, Tier A fact, but a voluntary-report signal with no established frequency or causal attribution, graded as a context flag under this category directly, never as an iron- or copper-deficiency claim.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None located specific to lacosamide. General pharmacovigilance practice notes that postmarketing reports cannot by themselves establish causation, which the label's own standard framing for this section already reflects.
  • At-risk subgroups: Not identifiable from a postmarketing-experience listing; no subgroup, dose, or exposure-duration breakdown is given.
  • Counter-evidence on record: Epilepsy patients on lacosamide are frequently on concomitant antiepileptic polytherapy, and other antiepileptic drugs (notably valproate and carbamazepine) carry their own well-documented myelosuppressive and hematologic risk; per Hard Rule 6, confounding by indication or by co-medication is presumed until excluded, and nothing located this session excludes it for this specific signal.

Regulatory status

Tier A: VIMPAT FDA-approved structured product label, Adverse Reactions section, postmarketing experience subsection, read directly via WebFetch this session: "Blood and lymphatic system disorders: neutropenia, anemia." No numerator, denominator, dose relationship, or onset timing is given, which is standard for a postmarketing-experience listing.

Population evidence

The label's postmarketing-experience section is itself the entire body of evidence located this session; it is derived from voluntary reports in a population of uncertain size taking lacosamide, mostly in combination with other antiepileptic drugs, not from a controlled trial arm with a defined denominator. No separate human study measuring hemoglobin, hematocrit, or neutrophil count as a function of lacosamide exposure was located (the combined PubMed query from the original pass, which included "hemoglobin," returned no relevant hit; see the Oxygen delivery/utilization history preserved in this entry's predecessor note below).

Mechanism

Not named. FDA postmarketing-experience sections report adverse events as observed, without requiring or asserting a mechanism; no bone-marrow-suppression or hemolytic mechanism specific to lacosamide's sodium-channel or CRMP2-binding pharmacology is documented anywhere located this session.

Counter-evidence held on record

This is a direct hematologic/oxygen-delivery category signal from the drug's own label, not an iron- or copper-deficiency finding, and it must never be read as grounds for iron or copper supplementation; those two entries are independently ungraded elsewhere in this dossier and are not supported by this fact. The signal's frequency and causal attribution to lacosamide specifically, versus the underlying epilepsy or concomitant antiepileptic drugs, are not established. It is distinct from, and must not be combined with, the drug's separately documented cardiac PR-interval/conduction effect (see Pharmacokinetic basis and Monitoring panel), which is lacosamide's own intended sodium-channel pharmacology, not a hematologic finding.

ATP production

Not graded — disclosed evidence gap

See study details

No grade assigned: the confirmed mitochondrial-morphology finding above did not measure ATP synthesis directly, no other Tier B/C lacosamide-specific evidence on ATP production was confirmed, and no circulating consumer claim was located to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: The Brustovetsky et al. 2023 mitochondrial-morphology finding (graded yellow under Mitochondrial burden) measured Drp1 recruitment, fragmentation, and organelle motility, not ATP synthesis or cellular energy output directly, so it is deliberately not carried over to this category as if it were ATP evidence (Hard Rule 7's instruction to keep this entry independent). An original-pass combined PubMed search including "ATP" alongside vitamin D/folate/vitamin K terms returned 24 results, none addressing ATP synthesis for lacosamide specifically. A repair-pass Crossref search dedicated to "lacosamide ATP mitochondrial energy metabolism" was run fresh this session and returned general bioenergetics literature (Aurora kinase/ATP synthase regulation, mitochondrial ATP-synthesis textbook chapters, mitochondrial energy-metabolism disease chapters, an ADP/ATP carrier review) with an explicit statement that the search did not return lacosamide-specific results at all. No circulating consumer "low energy" or ATP-depletion claim specifically naming lacosamide was located. The dual condition for ungraded (Step 7) is now met on two independently completed clean searches across two hosts.

Channels tried

Original pass, PubMed search-listing page, combined query "lacosamide ATP OR lacosamide vitamin D OR lacosamide folate OR lacosamide vitamin K": completed successfully, 24 results, top 10 reviewed by title (see Fails verification and Sources). Repair pass, Crossref API, dedicated query "lacosamide ATP mitochondrial energy metabolism": completed successfully via WebFetch, returned six results, all general bioenergetics literature with zero lacosamide-specific hits. Europe PMC, Semantic Scholar, OpenAlex, NCBI eutils, repair-pass PubMed: blocked this session by confirmed organization-level policy denial or 429 rejection. DailyMed/FDA label: re-read in full; no ATP or energy-metabolism language beyond general fatigue/dizziness listed as adverse reactions (a clinical-outcome side effect, not a measured ATP deficit, and not graded here per Hard Rule 2). General WebSearch: unavailable (budget exhausted, confirmed independently this repair pass).

Assessment

A genuine gap with moderate-to-good confidence: a dedicated, ATP-specific Crossref query now exists in addition to the original pass's broader combined query, and both are clean negatives for lacosamide specifically. Re-check PubMed, Europe PMC, Semantic Scholar, or OpenAlex directly once their organization-level policy blocks lift, since Crossref alone cannot be assumed to index every relevant mechanistic study.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Vitamin D

    Where it comes from: Generic drug-nutrient depletion handbooks and class-wide "anticonvulsants deplete vitamin D" lists that lump all antiseizure medications together, trading on the real, well-documented effect in phenytoin, carbamazepine, phenobarbital, and primidone. A PubMed search for "lacosamide vitamin D" (combined query, see ATP production entry) surfaced only class-wide bone-health and pharmacovigilance reviews (PMID 40889081, PMID 41689598, PMID 24821596) whose full text could not be opened this session to confirm whether lacosamide specifically was in their studied cohort.

    Why it fails: The mechanism these class-wide sources invoke is accelerated hepatic catabolism of vitamin D via CYP450 enzyme induction. Lacosamide's own label documents no induction or inhibition of any CYP450 enzyme by lacosamide itself (see Pharmacokinetic basis); the one mechanism that would support this claim is affirmatively absent from this drug's own chemistry, not merely unconfirmed. No lacosamide-specific study measuring vitamin D status was located despite a direct search. This is this drug's own pharmacology ruling the mechanism out.

  • Folate (folic acid)

    Where it comes from: The same class-wide depletion-handbook pattern as vitamin D, generalizing the documented folate-depletion effect of enzyme-inducing anticonvulsants to anticonvulsants as a class.

    Why it fails: Same mechanism-absence argument as vitamin D: folate depletion in anticonvulsant literature is attributed to accelerated catabolism via CYP450 induction, a mechanism lacosamide's own label rules out. No lacosamide-specific study measuring folate status was located. The placental-transport study found by title this session (Lacosamide effects on placental carriers of essential compounds in comparison with valproate, PMID 36056753) could not be opened to confirm whether folate specifically was among the "essential compounds" studied, so it is disclosed as a candidate but not used as support for this rebuttal or as a contradicting finding.

  • Vitamin K

    Where it comes from: Same class-wide handbook pattern, generalizing the documented vitamin K/neonatal coagulopathy risk of enzyme-inducing anticonvulsants (notably phenytoin, phenobarbital, primidone, carbamazepine) in pregnancy to anticonvulsants as a class.

    Why it fails: Same mechanism-absence argument: the vitamin K depletion signal in older anticonvulsants is attributed to CYP450-induction-accelerated catabolism of vitamin K, a mechanism absent from lacosamide's own documented pharmacology. No lacosamide-specific study measuring vitamin K status, neonatal coagulopathy, or bleeding risk was located this session.

  • Calcium / bone mineral density

    Where it comes from: Class-wide "antiseizure medications and bone health" literature, including two reviews found by title this session specifically concerning this topic (Antiseizure Medications and Bone Health, PMID 40889081; Evaluation of bone safety and antiseizure medications, a pharmacovigilance/Mendelian-randomization analysis, PMID 41689598), neither of which could be opened this session to confirm whether lacosamide specifically carried a signal distinct from the enzyme-inducing agents.

    Why it fails: The dominant mechanism for anticonvulsant-associated bone loss in the literature is the same vitamin-D-depletion-via-CYP-induction pathway addressed above, a mechanism lacosamide's own chemistry rules out; a smaller body of literature also describes direct osteoblast/osteoclast effects for specific older agents (notably valproate and phenytoin) independent of vitamin D, but no such direct-bone-cell mechanism or lacosamide-specific finding was located for lacosamide this session. Because the two most relevant bone-safety papers could not be opened, this rebuttal rests primarily on the absence of the induction mechanism (Pharmacokinetic basis) rather than on having directly excluded lacosamide from those two studies' cohorts; that partial verification is disclosed rather than treated as a complete cohort check.

How the body handles this medication

Metabolism and CYP450 induction/inhibition
Metabolized hepatically via CYP3A4, CYP2C9, and CYP2C19 to O-desmethyl-lacosamide, an inactive metabolite (about 30 percent of dose, about 10 percent of plasma exposure). No induction or inhibition of any CYP450 enzyme by lacosamide itself is documented in the label; strong CYP3A4/CYP2C9 inhibitors may raise lacosamide exposure, a drug-affecting-drug interaction, not a nutrient mechanism. This is the single most important fact in this dossier: the hepatic-enzyme-induction mechanism (Step 2, mechanism B) that drives the vitamin D, folate, and vitamin K depletion pattern documented for phenytoin, primidone, and phenobarbital-class agents elsewhere in this project is absent here.VIMPAT (lacosamide), FDA-approved structured product label via DailyMed, setid 9e79b42c-38a3-4b2c-a196-a5a1948250e2, UCB Inc, revised May 2026
Elimination route
Primarily renal: approximately 40 percent of a dose excreted unchanged in urine, approximately 30 percent as the inactive O-desmethyl metabolite, and approximately 20 percent as a structurally unidentified polar fraction. Lacosamide is effectively removed from plasma by hemodialysis; 50 percent supplemental dosing is advised post-dialysis. No renal-tubular-wasting mechanism (Step 2, mechanism C) for any specific electrolyte or nutrient is documented.VIMPAT FDA label via DailyMed, setid 9e79b42c-38a3-4b2c-a196-a5a1948250e2
Absorption
Oral bioavailability approximately 100 percent; completely absorbed, with negligible first-pass effect; time to peak concentration 1 to 4 hours; food does not affect the extent of absorption. No chelation, gastric-pH-dependent, or named-transporter absorption-interference mechanism (Step 2, mechanism A) is documented.VIMPAT FDA label via DailyMed, setid 9e79b42c-38a3-4b2c-a196-a5a1948250e2
Protein binding, distribution, half-life
Less than 15 percent bound to plasma proteins; volume of distribution approximately 0.6 L/kg; elimination half-life approximately 13 hours for unchanged drug (15 to 23 hours for the major metabolite). Low protein binding argues against a displacement-type nutrient-transport interaction.VIMPAT FDA label via DailyMed, setid 9e79b42c-38a3-4b2c-a196-a5a1948250e2
Renal and hepatic impairment
A 25 percent maximum dose reduction is recommended for severe renal impairment (creatinine clearance under 30 mL/min) and for mild-to-moderate hepatic impairment; use in severe hepatic impairment is not recommended. These are accumulation-risk adjustments for the drug itself, not evidence of a nutrient-wasting mechanism.VIMPAT FDA label via DailyMed, setid 9e79b42c-38a3-4b2c-a196-a5a1948250e2
Cardiac conduction (drug's own mechanism, not a nutrient finding)
Dose-related PR-interval prolongation is documented (mean increase approximately 7.3 ms at 400 mg/day, approximately 11.9 ms at 800 mg/day at steady state). Asymptomatic first-degree AV block occurred in 0.4 percent of VIMPAT patients versus 0 percent on placebo; one case of profound bradycardia (26 bpm) occurred during a 15-minute infusion; postmarketing reports include bradycardia, AV block, and ventricular tachyarrhythmia, rarely progressing to asystole, cardiac arrest, or death. This is lacosamide's own sodium-channel action extending to cardiac tissue (Hard Rule 2); it is not graded as an Oxygen delivery/utilization deficiency anywhere in this dossier and is instead carried into the Monitoring panel.VIMPAT FDA label via DailyMed, setid 9e79b42c-38a3-4b2c-a196-a5a1948250e2

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

  • Cardiac

    PR interval and conduction monitoring

    Lacosamide prolongs the PR interval in a dose-related fashion and carries rare reports of AV block, bradycardia, and ventricular tachyarrhythmia. Baseline and on-treatment ECG monitoring is reasonable in patients with known cardiac conduction disease or those on other PR-prolonging or heart-rate-lowering drugs. This is the drug's own pharmacology, not a nutrient deficiency, and no supplement addresses it.

  • Renal / hepatic

    Dose adjustment in impairment

    A 25 percent maximum dose reduction is recommended for severe renal impairment and for mild-to-moderate hepatic impairment; use in severe hepatic impairment is not recommended. Lacosamide is effectively removed by hemodialysis, and supplemental post-dialysis dosing is advised.

  • General

    No preemptive supplementation

    No entry in this dossier reaches a tier that supports a dosing recommendation. The two yellow entries are, mechanistic, protective findings in disease models, not human deficiency signals; every mandatory category not graded yellow is ungraded; and all four classical-nutrient entries are graded white, specifically rebutted. Yellow, white, and ungraded tiers are all barred from dosing recommendations by design.

  • Research re-check priority

    Categories to re-run when tooling recovers

    Copper and Iron (combined-term queries only on two hosts, no dedicated single-term follow-up on either). The Sodium/fluid balance case report (Gupta et al., 2018) should be opened in full once a paywall-free route is available, to confirm dose, sodium nadir, timeline, and rechallenge outcome. A second lacosamide/SIADH search should be re-run to check whether this is an isolated case or part of a small series.

  • Labs

    Serum sodium and CBC

    Not a routine requirement from this dossier's evidence (one case report and one postmarking-experience listing, both yellow-tier), but reasonable to keep in mind: a baseline and as-needed serum sodium if a patient develops hyponatremia symptoms (confusion, lethargy, nausea), and a baseline/as-needed CBC given the label's postmarketing neutropenia/anemia listing. Neither finding supports a sodium, iron, or copper supplement, and confounding by concomitant antiepileptic drugs or the underlying epilepsy is not excluded for either signal.

Overlap map, to prevent double counting

  • Vitamin D (Fails verification)

    Shares evidence with: Folate, Vitamin K, Calcium/bone mineral density (all Fails verification)

    Note: All four rebuttals rest on the same single Pharmacokinetic Basis fact: lacosamide's documented absence of CYP450 induction or inhibition. This is one mechanism-absence argument applied four times, not four independently confirmed findings that lacosamide is nutrient-safe.

  • Mitochondrial burden (yellow)

    Shares evidence with: Oxidative stress (yellow)

    Note: These two entries rest on different, independent primary sources (Brustovetsky et al. 2023, PMID 37174687, for mitochondrial morphology/motility; Shakeel et al. 2020, PMID 33316769, for oxidative-stress markers) studied in different models (Alzheimer's disease neurons versus lithium-pilocarpine status epilepticus). Stated explicitly here so a reader does not assume they independently corroborate a single broader "lacosamide protects cellular energy metabolism" claim; they are two separate, narrower findings.

  • Oxygen delivery/utilization (yellow, anemia/neutropenia signal)

    Shares evidence with: Pharmacokinetic basis "Cardiac conduction" fact; Monitoring panel, cardiac-conduction card

    Note: These are two separate FDA label facts, not one: the cardiac-conduction fact (PR-interval prolongation, AV block) and the postmarketing anemia/neutropenia fact are distinct passages of the same label, describing different organ systems. They must not be combined into a single larger "cardiovascular/hematologic" finding. The cardiac-conduction fact is disclosed once as the drug's own mechanism and routed to monitoring only; the anemia/neutropenia fact is graded yellow under Oxygen delivery/utilization. Neither is independent nutrient (iron/copper) evidence.

  • Oxygen delivery/utilization (yellow, anemia/neutropenia signal)

    Shares evidence with: Iron (ungraded); Copper (ungraded)

    Note: The label's postmarketing anemia/neutropenia listing must not be read as supporting evidence for either the Iron or Copper entry. Anemia is a clinical outcome, not a measured iron deficit (Hard Rule 2), and no copper- or iron-specific marker was named in that label passage or anywhere else located this session. Iron and Copper remain independently ungraded on their own search record.

  • Vitamin D / Folate / Vitamin K / Calcium-bone (Fails verification)

    Shares evidence with: Sibling anticonvulsant dossiers in this project's batch (ethosuximide, and the enzyme-inducing agents phenytoin, primidone, and phenobarbital-class drugs reviewed elsewhere in this series)

    Note: The class-wide contrast this dossier relies on, CYP-induction-mediated depletion present in the older agents and absent in lacosamide, is the same raw mechanistic contrast point used in this project's ethosuximide dossier (also a non-inducing agent, also graded white on vitamin D and folate for the identical reason) and implicitly referenced against the enzyme-inducing siblings. A reader must not treat lacosamide's white verdict here as having been independently re-derived from new lacosamide-specific data in each sibling dossier; it traces to the same single CYP-induction contrast point checked against this drug's own label.

All references used above
  1. VIMPAT (lacosamide), FDA-approved structured product label — Tablet, injection, and oral solution labeling (UCB, Inc.); Clinical Pharmacology, Warnings and Precautions, and Adverse Reactions sections read directly in full this session
  2. Shakeel W, Rahman SU, Rauf K, et al. Time course evaluation of lacosamide alone and in polypharmacy on behavioral manifestations and oxidative stress in a lithium-pilocarpine model of status epilepticus. J Physiol Pharmacol. 2020;71(4). — Rat lithium-pilocarpine status-epilepticus model; lacosamide alone (80 mg/kg) and in combination with pregabalin, piracetam, or scopolamine; full abstract read directly this session. Used as supporting evidence for the Oxidative stress entry (yellow).
  3. Brustovetsky T, Khanna R, Brustovetsky N. CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer's Disease. 2023. — In vitro study, cultured cortical neurons from APP/PS1 transgenic mice, plus postmortem human AD brain tissue analysis; full abstract read directly this session. Used as supporting evidence for the Mitochondrial burden entry (yellow). Access note: journal name, volume, and DOI could not be independently re-confirmed on a later follow-up request this session (429 rate-limit rejection); the abstract content itself was successfully retrieved and is used only for what it directly states.Access note: journal name, volume, and DOI could not be independently re-confirmed on a later follow-up request this session (429 rate-limit rejection); the abstract content itself was successfully retrieved and is used only for what it directly states.
  4. Nirwan N, Vyas P, Vohora D. Inverted-U response of lacosamide on pilocarpine-induced status epilepticus and oxidative stress. Epilepsy Res. 2018;145:93-101. — Title and PMID found via a completed PubMed search-listing page; suggests a lacosamide-specific, dose-dependent oxidative-stress finding Access note: the article-detail page returned a reCAPTCHA bot-verification page on every attempt made this session (more than five attempts across roughly 20 minutes with waits of 60 to 150 seconds between attempts). The full abstract could not be confirmed and this source is not used as support for any grade in this dossier.Access note: the article-detail page returned a reCAPTCHA bot-verification page on every attempt made this session (more than five attempts across roughly 20 minutes with waits of 60 to 150 seconds between attempts). The full abstract could not be confirmed and this source is not used as support for any grade in this dossier.
  5. Lazzarotto L, et al. Lacosamide improves biochemical, genotoxic, and mitochondrial parameters after PTZ-kindling. Fundam Clin Pharmacol. 2020;35(2):351-363. — Title and PMID found via a completed PubMed search-listing page; suggests a second lacosamide-specific protective mitochondrial/oxidative-stress finding in a PTZ-kindling model Access note: the article-detail page returned a reCAPTCHA bot-verification page on every attempt made this session. The full abstract could not be confirmed and this source is not used as support for any grade in this dossier.Access note: the article-detail page returned a reCAPTCHA bot-verification page on every attempt made this session. The full abstract could not be confirmed and this source is not used as support for any grade in this dossier.
  6. Savran M, et al. The Impact of Prophylactic Lacosamide on LPS-Induced Neuroinflammation. Inflammation. 2019;42(5):1913-1924. — Title and PMID found via a completed PubMed search-listing page; suggests a lacosamide-specific neuroinflammation finding Access note: full abstract not opened this session (search time was prioritized toward the two sources actually used). Not used as support for any grade.Access note: full abstract not opened this session (search time was prioritized toward the two sources actually used). Not used as support for any grade.
  7. Sumbul O, Aygun H. Electrocorticographic and electrocardiographic evaluation of lacosamide. Epilepsy Res. 2022;180:106866. — Title and PMID found via a completed PubMed search-listing page; relevant to the cardiac-conduction mechanism already confirmed via the FDA label Access note: full abstract not opened this session. Not used as support for any grade; the cardiac-conduction finding in this dossier rests on the Tier A FDA label instead.Access note: full abstract not opened this session. Not used as support for any grade; the cardiac-conduction finding in this dossier rests on the Tier A FDA label instead.
  8. Lacosamide effects on placental carriers of essential compounds in comparison with valproate: Studies in perfused human placentas. Epilepsia. 2022. — Title and PMID found via a completed PubMed search-listing page; potentially relevant to several classical nutrient entries if a specific carrier (folate, glucose, amino acid) were named Access note: the article-detail page returned a reCAPTCHA bot-verification page on every attempt made this session (more than four attempts with waits up to 170 seconds between attempts). Which carriers were studied, and lacosamide's direction of effect relative to control, could not be confirmed. Not used as support for any grade; flagged in Fails verification (Folate entry) as a candidate for future re-check.Access note: the article-detail page returned a reCAPTCHA bot-verification page on every attempt made this session (more than four attempts with waits up to 170 seconds between attempts). Which carriers were studied, and lacosamide's direction of effect relative to control, could not be confirmed. Not used as support for any grade; flagged in Fails verification (Folate entry) as a candidate for future re-check.
  9. Antiseizure medications and fetal nutrients: Effects on choline transporters in a human placental cell line. Epilepsia. 2021. — Title and PMID found via a completed PubMed search-listing page Access note: full abstract not opened this session (429 rejection on the one attempt made); whether lacosamide was among the antiseizure medications tested could not be confirmed (cohort test not completed). Not used as support for any grade.Access note: full abstract not opened this session (429 rejection on the one attempt made); whether lacosamide was among the antiseizure medications tested could not be confirmed (cohort test not completed). Not used as support for any grade.
  10. Antiseizure Medications and Bone Health. Neurol Ther. 2025. — Title and PMID found via a completed PubMed search-listing page; class-wide review Access note: full abstract not opened this session; whether lacosamide specifically carried a distinct (likely lower-risk, non-inducing) signal could not be confirmed. Not used as support for any grade; referenced only as the origin of the circulating calcium/bone claim in Fails verification.Access note: full abstract not opened this session; whether lacosamide specifically carried a distinct (likely lower-risk, non-inducing) signal could not be confirmed. Not used as support for any grade; referenced only as the origin of the circulating calcium/bone claim in Fails verification.
  11. Evaluation of bone safety and antiseizure medications: a multi-source pharmacovigilance and Mendelian randomization analysis. Naunyn Schmiedebergs Arch Pharmacol. 2026. — Title and PMID found via a completed PubMed search-listing page Access note: full abstract not opened this session (429 rejection on repeated attempts); whether lacosamide specifically was named with a signal, and in which direction, could not be confirmed. Not used as support for any grade; referenced only as the origin of the circulating calcium/bone claim in Fails verification.Access note: full abstract not opened this session (429 rejection on repeated attempts); whether lacosamide specifically was named with a signal, and in which direction, could not be confirmed. Not used as support for any grade; referenced only as the origin of the circulating calcium/bone claim in Fails verification.
  12. The problem of osteoporosis in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf. 2014. — Title and PMID found via a completed PubMed search-listing page; older class-wide review, title suggests focus on classic enzyme-inducing agents Access note: full abstract not opened this session; cohort not confirmed. Not used as support for any grade.Access note: full abstract not opened this session; cohort not confirmed. Not used as support for any grade.
  13. Pharmacological Incongruity of Lacosamide in the Management of Delirium Complicated by Ileus. Neuropsychopharmacol Rep. 2026. — Title and PMID found via a completed PubMed search-listing page while searching for gut microbiome evidence; concerns GI motility/ileus management, not microbiome composition
  14. Impact of Metabolic Surgery on Gut Microbiota and Sera Metabolomic Patterns among Patients with Diabetes. Int J Mol Sci. 2022. — Unrelated bariatric-surgery/diabetes microbiome study surfaced by the same gut-microbiome search; not a lacosamide study
  15. Pharmacokinetic interaction between modified Atkins diet and antiepileptic drugs in adults with drug-resistant epilepsy. Epilepsia. 2019. — Surfaced by the combined copper/iron/hemoglobin search; multi-drug ketogenic-diet pharmacokinetic study that incidentally measured hemoglobin A1c, not a lacosamide-copper or lacosamide-iron study specifically
  16. Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child. Front Pediatr. 2026. — Surfaced by the combined copper/iron/hemoglobin search; the myelodysplastic syndrome and hemoglobin finding (77 g/L) are attributed to valproate, with lacosamide present only as an adjunct medication in the case, not the causal agent
  17. Gupta SS, Patti R, Lindsay D, Raheja H, Kupfer Y. Lacosamide: Associated Hyponatremia. American Journal of Therapeutics. 2018. — Case report; title, authors, journal, and year confirmed directly via a completed Crossref API bibliographic search this repair pass. Used as the sole support for the Sodium/fluid balance entry (yellow); the title itself, naming lacosamide directly rather than a drug class, is what satisfies this protocol's cohort test, since the full case report could not be opened. Access note: a doi.org resolver request for this DOI returned an HTTP 402 payment-required paywall response. Three follow-up attempts to retrieve the abstract or full text, a Crossref works/{doi} metadata lookup, a PubMed search, and a Semantic Scholar search, were each rejected with HTTP 429 rate-limiting before completing. No dose, sodium level, timeline, or rechallenge detail from the case itself is known or cited anywhere in this dossier.Access note: a doi.org resolver request for this DOI returned an HTTP 402 payment-required paywall response. Three follow-up attempts to retrieve the abstract or full text, a Crossref works/{doi} metadata lookup, a PubMed search, and a Semantic Scholar search, were each rejected with HTTP 429 rate-limiting before completing. No dose, sodium level, timeline, or rechallenge detail from the case itself is known or cited anywhere in this dossier.
  18. Crossref API combined-term searches run this repair pass for Copper/Iron ("lacosamide copper iron"), Gut microbiome risk ("lacosamide gut microbiome microbiota dysbiosis"), and ATP production ("lacosamide ATP mitochondrial energy metabolism") — Each search completed successfully via WebFetch and returned only pharmacopeia/formulary monograph entries for lacosamide, unrelated metallurgy standards, unrelated microbiome studies in other conditions, or general bioenergetics literature, with no lacosamide-specific hit for any of the three categories. Listed here as a disclosed clean-negative search record, not as a citable finding; see the Copper, Iron, Gut microbiome risk, and ATP production entries for the full detail.